- Home
- PLX vs FORR Comparison
PLX vs FORR Comparison
Compare PLX & FORR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- FORR
- Stock Information
- Founded
- PLX 1993
- FORR 1983
- Country
- PLX United States
- FORR United States
- Employees
- PLX N/A
- FORR N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- FORR Diversified Commercial Services
- Sector
- PLX Health Care
- FORR Consumer Discretionary
- Exchange
- PLX Nasdaq
- FORR Nasdaq
- Market Cap
- PLX 160.2M
- FORR 179.6M
- IPO Year
- PLX 1998
- FORR 1996
- Fundamental
- Price
- PLX $1.55
- FORR $10.63
- Analyst Decision
- PLX Strong Buy
- FORR
- Analyst Count
- PLX 1
- FORR 0
- Target Price
- PLX $15.00
- FORR N/A
- AVG Volume (30 Days)
- PLX 1.4M
- FORR 68.0K
- Earning Date
- PLX 05-09-2025
- FORR 05-06-2025
- Dividend Yield
- PLX N/A
- FORR N/A
- EPS Growth
- PLX N/A
- FORR N/A
- EPS
- PLX 0.05
- FORR N/A
- Revenue
- PLX $59,764,000.00
- FORR $422,269,000.00
- Revenue This Year
- PLX $65.02
- FORR N/A
- Revenue Next Year
- PLX $57.34
- FORR $2.04
- P/E Ratio
- PLX $32.18
- FORR N/A
- Revenue Growth
- PLX 0.18
- FORR N/A
- 52 Week Low
- PLX $0.82
- FORR $8.50
- 52 Week High
- PLX $3.10
- FORR $20.62
- Technical
- Relative Strength Index (RSI)
- PLX 30.03
- FORR 55.44
- Support Level
- PLX $1.54
- FORR $10.39
- Resistance Level
- PLX $1.79
- FORR $10.91
- Average True Range (ATR)
- PLX 0.11
- FORR 0.46
- MACD
- PLX -0.02
- FORR 0.00
- Stochastic Oscillator
- PLX 27.27
- FORR 67.59
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.